Description: Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group's two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.
Home Page: www.amrytpharma.com
AMYT Technical Analysis
45 Mespil Road
Dublin,
4
Ireland
Phone:
353 1 518 0200
Officers
| Name | Title |
|---|---|
| Dr. Joseph A. Wiley | CEO & Director |
| Mr. Rory P. Nealon | CFO, COO & Company Sec. |
| Ms. Elizabeth Varki Jobes J.D. | Chief Compliance Officer |
| Mr. John McEvoy | Gen. Counsel |
| Mr. Stephen Joyce | Head of Marketing & Head of APAC |
| Ms. Julie Eastwood | Head of HR |
| Dr. Helen Phillips | Head of Medical Affairs |
| Ms. Sheila M. Frame | Pres of Americas |
| Dr. Tracy Cunningham | Chief Medical Officer |
| Mr. Jordi Casals | Pres of EMEA Region |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 67.5676 |
|---|---|
| Trailing PE: | 39.2703 |
| Price-to-Book MRQ: | 1.4007 |
| Price-to-Sales TTM: | 1.8749 |
| IPO Date: | 2019-12-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 289 |